I-Mab Soars 10.26% on Lucid Capital Buy Rating

Generado por agente de IAAinvest Pre-Market Radar
jueves, 29 de mayo de 2025, 7:06 am ET1 min de lectura
IMAB--

On May 29, 2025, I-Mab's stock surged by 10.26% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Lucid Capital recently initiated a buy rating for I-MabIMAB--, setting a target price of $5. This move comes as the stock has demonstrated strong momentum, gaining over 10% in the past week and 22% year-to-date. The firm's analyst emphasized I-Mab Biopharma's focus on precision medicine and its robust pipeline of innovative therapies, which are expected to drive future growth.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios